Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492778 | PMC |
| http://dx.doi.org/10.1111/cns.12652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Peste des petits ruminants: past, present, and future scope.
J Infect Dev Ctries
December 2024
Department of Veterinary Medicine, Faculty of Agriculture and Veterinary Medicine, An-Najah National University, Nablus, Palestine.
Introduction: Peste des petits ruminants (PPR) is a highly contagious and fatal disease affecting small ruminants, particularly goats and sheep, and is caused by Morbillivirus caprinae, a virus in the genus Morbillivirus, family Paramyxoviridae. PPR has significant economic and social impacts, especially in Africa, Asia, and the Middle East, where small ruminants are vital to rural livelihoods and food security. This disease is a priority for global eradication due to its disproportionate impact on low-income farmers and wildlife conservation.
View Article and Find Full Text PDFEvolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma.
Curr Oncol Rep
January 2025
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Purpose Of Review: This review addresses the current treatment paradigm and new advancements in the management of microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) esophagogastric cancer (EGC).
Recent Findings: While chemotherapy and surgery remain the cornerstone of EGC treatment, MSI-H/dMMR tumors harbor high tumor mutational burden and represent a subset of patients who benefit from immune checkpoint inhibitors (ICI). ICI has been incorporated in the front line setting with and without chemotherapy for advanced disease.
The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review.
J Thorac Dis
December 2024
Department of Surgery, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Background And Objective: Lung cancer recurrence after complete surgical resection of early-stage T1-T2N0 non-small cell lung cancer (NSCLC) remains a problem due to unrecognized micrometastatic disease. The objective of this review is to present and summarize data from major randomized trials in which have studied the survival benefit of adjuvant therapy for early-stage NSCLC.
Methods: Information used to write this paper was collected from PubMed and the National Clinical Trial registry from the National Library of Medicine.
Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.
Transl Lung Cancer Res
December 2024
Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State University, Hershey, PA, USA.
Background: Predictive biomarkers for immune checkpoint inhibitors (ICIs), e.g., programmed death ligand-1 (PD-L1) tumor proportional score (TPS), remain limited in clinical applications.
View Article and Find Full Text PDFHealth-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.
Transl Lung Cancer Res
December 2024
Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Background: Health-related quality of life (HRQoL) is critical for patients with lung cancer due to poor prognosis. We presented patient-reported outcomes in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) who received whole-brain radiotherapy (WBRT) in combination with erlotinib or WBRT alone in the phase 3 ENTER study.
Methods: The patients' HRQoL was assessed by using the European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire (EORTC QLQ-C30).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!